Status:
COMPLETED
To Evaluate the Response to Glucagon During Hypoglycemia
Lead Sponsor:
AstraZeneca
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the response to Glucagon versus the spontaneous hormonal response to low blood sugar levels in T2DM Patients treated with AZD1656 and Metformin
Eligibility Criteria
Inclusion
- type II diabetes patients, female with non child-bearing potential
- T2DM diagnosis confirmed by C-peptide \>0.3nmol/L and no glutamic acid decarboxylate (GAD) antibodies at enrolment (screening)
- Treatment with metformin alone with a total daily dose not less than 1 000 mg. Stable glycaemic control indicated by unchanged treatment within 3 months prior to enrolment
Exclusion
- History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease
- Signs of diabetic proliferative retinopathy or diabetic maculopathy, at screening or on an ophthalmological examination within 3 months from start of study
- Participating in another clinical study during the last 30 days prior to enrolment
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00817271
Start Date
February 1 2009
End Date
April 1 2009
Last Update
May 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Chula Vista, California, United States